ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ: ANIP · Real-Time Price · USD
64.97
-1.13 (-1.71%)
At close: Jul 11, 2025, 4:00 PM
64.96
-0.01 (-0.02%)
After-hours: Jul 11, 2025, 4:20 PM EDT
ANI Pharmaceuticals Stock Forecast
Stock Price Forecast
The 9 analysts that cover ANI Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $80.56, which forecasts a 24% increase in the stock price over the next year. The lowest target is $65 and the highest is $94.
Price Target: $80.56 (+24%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ANI Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 3 | 3 | 3 | 3 | 4 |
Buy | 4 | 4 | 4 | 4 | 4 | 4 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 7 | 8 | 8 | 8 | 8 | 9 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $84 | Strong Buy | Initiates | $84 | +29.29% | Jul 10, 2025 |
Guggenheim | Guggenheim | Strong Buy Reiterates $86 | Strong Buy | Reiterates | $86 | +32.37% | May 12, 2025 |
Truist Securities | Truist Securities | Hold Maintains $62 → $65 | Hold | Maintains | $62 → $65 | +0.05% | Apr 21, 2025 |
Guggenheim | Guggenheim | Strong Buy Reiterates $86 | Strong Buy | Reiterates | $86 | +32.37% | Apr 11, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $94 | Strong Buy | Reiterates | $94 | +44.68% | Mar 17, 2025 |
Financial Forecast
Revenue This Year
803.84M
from 614.38M
Increased by 30.84%
Revenue Next Year
863.25M
from 803.84M
Increased by 7.39%
EPS This Year
6.65
from -1.04
EPS Next Year
7.22
from 6.65
Increased by 8.48%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 836.4M | 925.7M | 1.0B | ||
Avg | 803.8M | 863.3M | 922.0M | ||
Low | 765.4M | 804.0M | 830.8M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 36.1% | 15.2% | 16.0% | ||
Avg | 30.8% | 7.4% | 6.8% | ||
Low | 24.6% | 0.0% | -3.8% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 6.94 | 8.48 | 10.43 | ||
Avg | 6.65 | 7.22 | 8.38 | ||
Low | 6.26 | 6.04 | 6.96 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | 27.5% | 44.5% | ||
Avg | - | 8.5% | 16.1% | ||
Low | - | -9.3% | -3.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.